Drotrecogin alfa (activated)

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Sepsis

Conditions

Sepsis

Trial Timeline

Sep 1, 2002 → —

NCT ID

NCT00045760

About Drotrecogin alfa (activated)

Drotrecogin alfa (activated) is a approved stage product being developed by Eli Lilly for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00045760. Target conditions include Sepsis.

What happened to similar drugs?

8 of 18 similar drugs in Sepsis were approved

Approved (8) Terminated (1) Active (9)

✅MeropenemPfizerApproved

✅ImipenemMerckApproved

✅Drotrecogin Alfa (activated)Eli LillyApproved

✅Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved

✅drotrecogin alfa (activated)Eli LillyApproved

✅Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00386425	Phase 2	Completed	Nov 1, 2006	Aug 1, 2009	Severe Sepsis
NCT00279214	Approved	Completed	Nov 1, 2005	Nov 1, 2007	Sepsis
NCT00067730	Approved	Completed	Mar 1, 2003	Oct 1, 2003	Sepsis
NCT00568893	Approved	Completed	Jan 1, 2003	Oct 1, 2003	Severe Sepsis
NCT00045760	Approved	Completed	Sep 1, 2002	—	Sepsis

Competing Products

20 competing products in Sepsis

See all competitors

Product	Company	Stage	Hype Score
Alkaline Phosphatase + Placebo	AM-Pharma	Phase 2	25
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	35
Meropenem	Pfizer	Approved	43
Imipenem	Merck	Approved	39
Cefiderocol	Shionogi	Phase 1	29
eritoran tetrasodium + Placebo	Eisai	Phase 3	40
E5564	Eisai	Phase 2	35
Drotrecogin Alfa (Activated) + placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin Alfa (activated)	Eli Lilly	Approved	43
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
sPLA2 Inhibitor	Eli Lilly	Phase 1/2	32
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
AZD9773 (CytoFab)	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35
AZD4144 + Placebo	AstraZeneca	Phase 2	42